MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Clinical trials for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney diseases: early access drug available
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and kidney damage. Participants must have active disease and limited response to other treatments. The …
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 08:13 UTC
-
New hope for rare kidney patients: Long-Term drug trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New tests could transform care for rare kidney diseases
Knowledge-focused OngoingThis study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: aHUS and C3G. Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers. The goal is to find markers that help doctors choose the right treatment …
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: NA • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated May 14, 2026 12:07 UTC